HRP20120577T1 - 3,4-diarilpirazoli kao inhibitori proteinskih kinaza - Google Patents

3,4-diarilpirazoli kao inhibitori proteinskih kinaza Download PDF

Info

Publication number
HRP20120577T1
HRP20120577T1 HRP20120577AT HRP20120577T HRP20120577T1 HR P20120577 T1 HRP20120577 T1 HR P20120577T1 HR P20120577A T HRP20120577A T HR P20120577AT HR P20120577 T HRP20120577 T HR P20120577T HR P20120577 T1 HRP20120577 T1 HR P20120577T1
Authority
HR
Croatia
Prior art keywords
pyrazol
pyridin
phenyl
optionally substituted
trifluoromethylphenyl
Prior art date
Application number
HRP20120577AT
Other languages
English (en)
Croatian (hr)
Inventor
Pulici Maurizio
Zuccotto Fabio
Badari Alessandra
Nuvoloni Stefano
Cervi Giovanni
Traquandi Gabriella
Biondaro Sonia
Trifiro' Paolo
Marchionni Chiara
Modugno Michele
Original Assignee
Nerviano Medical Sciences S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41059486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120577(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences S.R.L. filed Critical Nerviano Medical Sciences S.R.L.
Publication of HRP20120577T1 publication Critical patent/HRP20120577T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20120577AT 2008-07-24 2009-07-23 3,4-diarilpirazoli kao inhibitori proteinskih kinaza HRP20120577T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161076 2008-07-24
PCT/EP2009/059506 WO2010010154A1 (en) 2008-07-24 2009-07-23 3,4-diarylpyrazoles as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20120577T1 true HRP20120577T1 (hr) 2012-08-31

Family

ID=41059486

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120577AT HRP20120577T1 (hr) 2008-07-24 2009-07-23 3,4-diarilpirazoli kao inhibitori proteinskih kinaza

Country Status (19)

Country Link
US (2) US8541575B2 (enExample)
EP (1) EP2324008B1 (enExample)
JP (1) JP5385382B2 (enExample)
CN (1) CN102105459B (enExample)
AT (1) ATE557015T1 (enExample)
AU (1) AU2009273197B2 (enExample)
BR (1) BRPI0916356B1 (enExample)
CA (1) CA2731146C (enExample)
CL (1) CL2011000124A1 (enExample)
CY (1) CY1117667T1 (enExample)
DK (1) DK2324008T3 (enExample)
EA (1) EA019722B1 (enExample)
ES (1) ES2386408T3 (enExample)
HR (1) HRP20120577T1 (enExample)
MX (1) MX2011000738A (enExample)
PL (1) PL2324008T3 (enExample)
PT (1) PT2324008E (enExample)
SI (1) SI2324008T1 (enExample)
WO (1) WO2010010154A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
PL2324008T3 (pl) * 2008-07-24 2012-09-28 Nerviano Medical Sciences Srl 3,4-diarylopirazole jako inhibitory kinazy białkowej
JP5603869B2 (ja) 2008-09-29 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AR077975A1 (es) * 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CN104958294A (zh) * 2010-01-27 2015-10-07 内尔维安诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
WO2011117381A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
KR20130048293A (ko) * 2010-06-25 2013-05-09 노파르티스 아게 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
JP5938038B2 (ja) * 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用
TWI480276B (zh) * 2010-08-27 2015-04-11 Irm Llc 作為蛋白質激酶抑制劑之化合物及組合物
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
JP5998152B2 (ja) * 2011-01-25 2016-09-28 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン Ｂｃｌ−２／ｂｃｌ−ｘｌ阻害剤およびそれを使用する治療方法
WO2012113774A1 (en) 2011-02-24 2012-08-30 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
KR101298651B1 (ko) * 2011-03-16 2013-08-21 연세대학교 산학협력단 효능이 강화된 혈관신생 억제용 약제학적 조성물
JP6211522B2 (ja) 2011-10-06 2017-10-11 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ヘテロシクリルピリ（ミ）ジニルピラゾール
UA114490C2 (uk) 2011-10-06 2017-06-26 Байєр Інтеллектуал Проперті Гмбх Гетероциклілпіри(mі)динілпіразоли як фунгіциди
US11007194B2 (en) 2011-11-11 2021-05-18 Array Biopharma Inc. Method of treating a proliferative disease
WO2013078264A1 (en) 2011-11-23 2013-05-30 Novartis Ag Pharmaceutical formulations
CN105008344B (zh) 2012-11-02 2017-07-25 辉瑞公司 布鲁顿氏酪氨酸激酶抑制剂
SG11201505525UA (en) 2013-01-16 2015-08-28 Univ Michigan Bcl-2bcl-xl inhibitors and therapeutic methods using the same
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2016160881A1 (en) 2015-04-01 2016-10-06 Rigel Pharmaceuticals, Inc. TGF-β INHIBITORS
MX2018001464A (es) * 2015-08-03 2018-05-28 Glenmark Pharmaceuticals Sa Compuestos nuevos como moduladores de ror gamma.
CN114685516A (zh) 2015-09-16 2022-07-01 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
ES2828431T3 (es) * 2015-12-16 2021-05-26 Loxo Oncology Inc Compuestos útiles como inhibidores de cinasa
BR112018074941A2 (pt) 2016-06-03 2019-03-12 Caponigro Giordano combinações farmacêuticas
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
CN106883266B (zh) * 2017-01-23 2020-03-17 江苏七洲绿色化工股份有限公司 一种1-(4-氯苯基)-2-环丙基-1-丙酮的制备方法及其中间体
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
WO2019081485A1 (de) 2017-10-26 2019-05-02 Bayer Cropscience Aktiengesellschaft Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe
WO2019081477A1 (de) 2017-10-26 2019-05-02 Bayer Cropscience Aktiengesellschaft Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11053221B2 (en) * 2018-10-26 2021-07-06 Arrien Pharmaceuticals Llc Substituted pyrimidines for inhibiting embryonic leucine zipper kinase activity
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
WO2020245044A1 (de) 2019-06-03 2020-12-10 Bayer Aktiengesellschaft 1-phenyl-5-azinylpyrazolyl-3-oxyalkylsäuren und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
CN119930611A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
KR102323820B1 (ko) * 2019-10-31 2021-11-08 한국화학연구원 돌연변이형 idh 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
CN112979613B (zh) * 2019-12-16 2022-04-26 四川大学华西医院 2-(1h-吡唑-3-基)吡啶衍生物及其制备方法和用途
WO2021122728A1 (de) 2019-12-19 2021-06-24 Bayer Aktiengesellschaft 1,5-diphenylpyrazolyl-3-oxyalkylsäuren und 1-phenyl-5-thienylpyrazolyl-3-oxyalkylsäuren und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
BR112022012674A2 (pt) 2020-01-31 2022-09-06 Bayer Ag Derivados de ácido [(1,4,5-trissubstituído-1h-pirazol-3-il)sulfanil]acético e sais dos mesmos e uso dos mesmos como ingredientes herbicidas ativos
TW202204354A (zh) * 2020-04-02 2022-02-01 美商普雷辛肯公司 用於ｃｓｋ調節之化合物及方法以及其說明
US20230167088A1 (en) 2020-04-29 2023-06-01 Bayer Aktiengesellschaft 1-pyrazinylpyrazolyl-3-oxyalkyl acids and their derivatives, and their use for control of undesired plant growth
AU2021289163B2 (en) 2020-06-09 2024-05-02 Array Biopharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of BRAF-associated diseases and disorders
CN116368129A (zh) 2020-10-23 2023-06-30 拜耳公司 1-(吡啶基)-5-吖嗪基吡唑衍生物及其用于控制有害的植物生长的用途
MX2023005078A (es) * 2020-10-30 2023-05-16 Novartis Ag Nuevas formas cristalinas de un compuesto inhibidor de kras g12c.
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
KR20240025627A (ko) 2021-06-25 2024-02-27 바이엘 악티엔게젤샤프트 (1,4,5-삼치환된-1h-피라졸-3-일)옥시-2-알콕시 알킬 산 및 그의 유도체, 그의 염 및 제초제로서의 그의 용도
WO2023091873A1 (en) * 2021-11-19 2023-05-25 The Board Of Trustees Of The University Of Illinois Gram-negative specific antibiotics sparing effect on gut microbiome
MX2024006672A (es) 2021-12-01 2024-06-19 Bayer Ag Acidos de (1h-pirazol-3-il)oxi-2-alquiltio-alquilo 1,4,5-trisustituidos y derivados del acidos de (1h-pirazol-3-il)oxi-2-alquiltio-alquilo 1,4,5-trisustituido, sus sales y su uso como principios activos herbicidas.
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
KR20240167846A (ko) 2022-03-28 2024-11-28 니캉 테라퓨틱스 인코포레이티드 사이클린 의존적 키나제 2 억제제로서의 설폰아미도 유도체
WO2024078871A1 (de) 2022-10-14 2024-04-18 Bayer Aktiengesellschaft 1-pyridyl-5-phenylpyrazolyl-3-oxy- und -3-thioalkylsäuren und derivate und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JP2002508754A (ja) 1997-05-22 2002-03-19 ジー ディ サール アンド カンパニ ｐ３８キナーゼ阻害剤としての置換基を有するピラゾール類
EP1456180B1 (en) 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use
EP1706400A1 (en) * 2004-01-09 2006-10-04 Novartis AG Phenyl- 4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl -amine derivatives as igf-ir inhibitors
EP1917258A2 (en) 2005-08-26 2008-05-07 SmithKline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
CA2643066A1 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
MX2009003456A (es) * 2006-10-02 2009-04-14 Irm Llc Compuestos y composiciones como inhibidores de proteina cinasa.
PL2324008T3 (pl) * 2008-07-24 2012-09-28 Nerviano Medical Sciences Srl 3,4-diarylopirazole jako inhibitory kinazy białkowej
CN104958294A (zh) * 2010-01-27 2015-10-07 内尔维安诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物
JP5938038B2 (ja) 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用

Also Published As

Publication number Publication date
CA2731146A1 (en) 2010-01-28
BRPI0916356A2 (enExample) 2018-08-21
AU2009273197B2 (en) 2014-01-16
EA019722B1 (ru) 2014-05-30
US20110144068A1 (en) 2011-06-16
JP5385382B2 (ja) 2014-01-08
WO2010010154A1 (en) 2010-01-28
EP2324008A1 (en) 2011-05-25
HK1157337A1 (en) 2012-06-29
CY1117667T1 (el) 2017-05-17
AU2009273197A1 (en) 2010-01-28
EP2324008B1 (en) 2012-05-09
CA2731146C (en) 2016-05-03
CN102105459B (zh) 2014-09-10
ATE557015T1 (de) 2012-05-15
CL2011000124A1 (es) 2011-05-06
DK2324008T3 (da) 2012-07-23
JP2011528698A (ja) 2011-11-24
PT2324008E (pt) 2012-06-25
BRPI0916356B1 (pt) 2022-08-23
US20140005150A1 (en) 2014-01-02
CN102105459A (zh) 2011-06-22
ES2386408T3 (es) 2012-08-20
AU2009273197A2 (en) 2011-03-10
MX2011000738A (es) 2011-02-23
EA201170249A1 (ru) 2011-10-31
US8541575B2 (en) 2013-09-24
US8946250B2 (en) 2015-02-03
PL2324008T3 (pl) 2012-09-28
SI2324008T1 (sl) 2012-08-31

Similar Documents

Publication Publication Date Title
CN100563651C (zh) 具有cb1-拮抗活性的1,3,5-三取代的4,5-二氢-1h-吡唑衍生物
RU2411238C2 (ru) Цис-2,4,5-триарилимидазолины и их применение в качестве противораковых лекарственных средств
RU2475487C2 (ru) Имидазохинолины с иммуномодулирующими свойствами
US9790173B2 (en) Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I
ES2305317T3 (es) Derivados de amida bifenilcarboxilico como inhibidores de quinasa p38.
RU2004135304A (ru) Производные 2,6-хинолинила и 2,6-нафтила, способы их получения и их применение в качестве ингибиторов vla-4
RU2361868C2 (ru) Новые производные тиазола
RU2003128992A (ru) Омега-аминоалкиламиды r-2-арилпропионовых кислот в качестве ингибиторов хемотаксиса полиморфноядерных и одноядерных клеток
JP2013507449A5 (enExample)
AU2007219509A1 (en) Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
US20060128690A1 (en) Amine derivative
JP2004523534A5 (enExample)
JP4825664B2 (ja) ピペラジン−２−カルボキサミド誘導体
JP2003510319A5 (enExample)
RU2011134052A (ru) Новые бензолсульфонамиды в качестве блокаторов кальциевых каналов
CA2379575A1 (en) Pharmaceutically active sulfonamide derivatives
RU2004100839A (ru) Производные пиперидина полезные в качестве модуляторов активности рецепторов хемокинов
CN101018774A (zh) α7烟碱性乙酰胆碱受体的调节剂和其治疗用途
CN101925573A (zh) 新型的n-(2-氨基-苯基)-酰胺衍生物
JP2020515516A5 (enExample)
CA2742906A1 (en) Substituted amido phenoxybenzamides
PT1828148E (pt) Compostos de amino benzofenona substituídos por triazol
HRP20161260T1 (hr) Derivati (r)-arilkilamina i farmaceutski pripravci koji ih sadrže
JP6313264B2 (ja) ケイ皮酸アミド誘導体を含有する医薬
JP6415985B2 (ja) ケイ皮酸アミド誘導体